Determining appropriate substrate conversion for enzymatic assays in high-throughput screening

被引:57
作者
Wu, G
Yuan, Y
Hodge, CN
机构
[1] Five Prime Therapeut, San Francisco, CA 94080 USA
[2] Amphora Discovery Corp, Los Altos, CA USA
关键词
enzyme; substrate; conversion; screening; kinetics;
D O I
10.1177/1087057103260050
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
It is generally accepted that the conversion of substrate should be kept at less than 10% of the total substrate used when studying enzyme kinetics. However, 10% or less substrate conversion often will not produce sufficient signal changes required for robust high-throughput screening (HTS). To increase the signal-to-background ratio, HTS is often performed at higher than 10% substrate conversion. Because the consequences of high substrate conversion are poorly understood, the screening results are sometimes questioned by enzymologists. The quality of an assay is judged by the ability to detect an inhibitor under HTS conditions, which depends on the robustness of the primary detection signal (Z factor) and the sensitivity to an inhibitor. The assay sensitivity to an inhibitor is reflected in the observed IC50 value or percent inhibition at a fixed compound concentration when single-point data are collected. The major concern for an enzymatic assay under high substrate conversion is that the sensitivity of the screen may be compromised. Here we derive the relationship between the IC50 value for a given inhibitor and the percentage of substrate conversion using a first-order kinetic model under conditions that obey Henri-Michaelis-Menten kinetics. The derived theory was further verified experimentally with a cAMP-dependent protein kinase. This model provides guidance for assay developers to choose an appropriate substrate conversion in designing an enzymatic assay, balancing the needs for robust signal and sensitivity to inhibitors.
引用
收藏
页码:694 / 700
页数:7
相关论文
共 12 条
[1]   Bimodal inhibition of caspase-1 by aryloxymethyl and acyloxymethyl ketones [J].
Brady, KD .
BIOCHEMISTRY, 1998, 37 (23) :8508-8515
[2]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[3]  
Chung TDY, 2001, DRUGS PHARM SCI, V114, P283
[4]  
Copeland R. A., 2004, ENZYMES PRACTICAL IN
[5]   The druggable genome [J].
Hopkins, AL ;
Groom, CR .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (09) :727-730
[6]  
Macarron Ricardo, 2002, Methods Mol Biol, V190, P1
[7]  
Manly SP, 1997, J BIOMOL SCREEN, V2, P197
[8]  
Segel I., 1976, ENZYME KINETICS BEHA
[9]  
SPECTOR DL, 1997, CELLS LAB MANUAL
[10]  
Walsh C., 1979, ENZYMATIC REACTION M